Maureen M. Goodenow, Ph.D.

Chief, Molecular HIV Host Interactions Section

Director, NIH Office of AIDS Research

Contact Information

Major Areas of Research

Interactions between HIV-1 and host, in particular children, adolescents, and young adults, at the molecular level

View all Division of Intramural Research laboratories

Program Description

The major research focus of the Molecular HIV Host Interactions Section is to investigate interactions between HIV-1 and host, in particular children, adolescents, and young adults, at the molecular level, which includes the following:

HIV-mediated chronic systematic immune activation, perturbation, and efficiency in B cells, T cells, and macrophages
Influence of recreational substance use, e.g., marijuana, tobacco products, and alcohol, on HIV-modulated gene expression and functional pathways
HIV-1 cell tropism, potency, reservoir, reactivation, and molecular evolution of the HIV-1 genome over the course of infection with/without antiretroviral therapy

Biography

Dr. Goodenow received her undergraduate degree in biology from Fordham University and her Ph.D. in molecular genetics from the Albert Einstein College of Medicine. Following a postdoctoral fellowship in molecular oncology at the Sloan Kettering Institute, Dr. Goodenow was a visiting scientist at the Pasteur Institute in Paris, where she began her study of HIV.

Dr. Goodenow was a professor of pathology, immunology, and laboratory medicine at the University of Florida, Gainesville, where she held the Stephany W. Holloway University Endowed Chair for AIDS Research. She also was the Director of the Center for Research in Pediatric Immune Deficiency Diseases.

She served as the acting director of the Office for Research and Science in the U.S. Department of State, Office of the U.S. Global AIDS Coordinator, and Office of Global Health Diplomacy. Dr. Goodenow was the 2012 recipient of the prestigious Jefferson Science Fellowship at the State Department, where she served as senior science advisor in the Office of Economic Policy’s Bureau of East Asian and Pacific Affairs.

Dr. Goodenow was appointed associate director for AIDS Research at NIH and director of the NIH Office of AIDS Research in 2016, coordinating the HIV/AIDS research agenda across NIH. She also is chief of the Molecular HIV Host Interactions Section.

Dr. Goodenow is the recipient of the Gertrude and Herman Silver 24th Annual Lecture Award and the Wistar Institute’s Jonathan Lax Memorial Award.

She continues to invest in the next generation of scientists and has trained more than 50 doctoral and postdoctoral fellows. A respected, peer-reviewed author, Dr. Goodenow has published more than 100 articles and book chapters, in addition to serving as a reviewer for more than 10 journals.

Research Group

Li Yin, staff scientist

Kai-Fen Chang, biologist

Samiksha Borkar, technician

Selected Publications

Yin L, Chang KF, Nakamura KJ, Kuhn L, Aldrovandi GM, Goodenow MM. Unique genotypic features of HIV-1 C gp41 membrane proximal external region variants during pregnancy relate to mother-to-child transmission via breastfeeding. J Clin Pediatr Neonatol. 2021;1(1):9-20.

Baloh CH, Borkar SA, Chang KF, Yao J, Hershfield MS, Parikh SH, Kohn DB, Goodenow MM, Sleasman JW, Yin L. Normal IgH Repertoire Diversity in an Infant with ADA Deficiency After Gene Therapy. J Clin Immunol. 2021 Oct;41(7):1597-1606.

Dybul M, Attoye T, Baptiste S, Cherutich P, Dabis F, Deeks SG, Dieffenbach C, Doehle B, Goodenow MM, Jiang A, Kemps D, Lewin SR, Lumpkin MM, Mathae L, McCune JM, Ndung'u T, Nsubuga M, Peay HL, Pottage J, Warren M, Sikazwe I; Sunnylands 2019 Working Group. The case for an HIV cure and how to get therev. Lancet HIV. 2021 Jan;8(1):e51-e58.

Bekker LG, Tatoud R, Dabis F, Feinberg M, Kaleebu P, Marovich M, Ndung'u T, Russell N, Johnson J, Luba M, Fauci AS, Morris L, Pantaleo G, Buchbinder S, Gray G, Vekemans J, Kim JH, Levy Y, Corey L, Shattock R, Makanga M, Williamson C, Dieffenbach C, Goodenow MM, Shao Y, Staprans S, Warren M, Johnston MI. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet. 2020 Feb;395(10221):384-388.

Kim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2019 Aug;35(8):746-754.

Kim-Chang JJ, Donovan K, Loop MS, Hong S, Fischer B, Venturi G, Garvie PA, Kohn J, Rendina HJ, Woods SP, Goodenow MM, Nichols SL, Sleasman JW; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Higher soluble CD14 levels are associated with lower visuospatial memory performance in youth with HIV. AIDS. 2019 Dec;33(15):2363-2374.

Visit PubMed for a complete publication listing.

Section or Unit Name

Molecular HIV Host Interactions Section

Lab/Program Name

Molecular HIV Host Interactions Section

First Name

Maureen

Last Name

Goodenow

Middle Name

Suffix

Ph.D.

Exclude from directory

Off

Section/Unit: Location

NIH Main Campus, Bethesda, MD

This Researcher/Clinician’s Person Page

Maureen M. Goodenow, Ph.D.

Program Description

Effect of recreational substance use, e.g., marijuana, tobacco products, and alcohol, on gene expression and biological pathways in youth with HIV (YWH) on antiretroviral therapy (ART).
Transcriptome bioprofiles in HIV-exposed but uninfected (HEU) children in comparison to HIV-unexposed and uninfected (HUU) children.
HIV-1 cell tropism, latency, reservoir, reactivation, and evolution of the HIV-1 genome over the course of infection with/without ART.
Development and maturation of immunoglobulin repertoires, and response to vaccines in early human life.

Selected Publications

Yin L, Dinasarapu AR, Borkar SA, Chang KF, De Paris K, Kim-Chang JJ, Sleasman JW, Goodenow MM. Anti-inflammatory effects of recreational marijuana in virally suppressed youth with HIV-1 are reversed by use of tobacco products in combination with marijuana. Retrovirology. 2022 May 31;19(1):10.

Visit PubMed for a complete publication listing.

Major Areas of Research

Effect of recreational substance use, e.g., marijuana, tobacco products, and alcohol, on gene expression and biological pathways in youth with HIV (YWH) on antiretroviral therapy (ART).
Transcriptome bioprofiles in HIV-exposed but uninfected (HEU) children in comparison to HIV-unexposed and uninfected (HUU) children.
HIV-1 cell tropism, latency, reservoir, reactivation, and evolution of the HIV-1 genome over the course of infection with/without ART.
Development and maturation of immunoglobulin repertoires, and response to vaccines in early human life.

Research Group Page

Goodenow Research Group

John Misasi, M.D.

Contact: For contact information, search the NIH Enterprise Directory.

Specialty(s): Infectious Disease, Pediatrics
Provides direct clinical care to patients at NIH Clinical Center

Education:

M.D., 2002, SUNY Upstate Medical University, Syracuse, NY

B.S., 1996, Boston University, MA

Joshua R. Lacsina, M.D., Ph.D.

Contact: For contact information, search the NIH Enterprise Directory.

Specialty(s): Infectious Disease, Internal Medicine
Provides direct clinical care to patients at NIH Clinical Center

Education:

M.D., Ph.D., Duke University

A.B., Harvard University

Joshua R. Lacsina, M.D., Ph.D.

Assistant Clinical Investigator

Section or Unit Name

Multiscale Systems Biology Section

Lab/Program Name

Laboratory of Immune System Biology

First Name

Joshua

Last Name

Lacsina

Middle Name

Exclude from directory

Off

Section/Unit: Location

NIH Main Campus, Bethesda, MD

This Researcher/Clinician’s Person Page

Joshua R. Lacsina, M.D., Ph.D.

Parent Lab/Program

Laboratory of Immune System Biology

Program Description

The Lacsina Laboratory applies systems immunology approaches to investigate human skin immunity to the protozoan parasite Leishmania. The parasite is transmitted to humans via the bite of infected female sand fly vectors, with skin infection leading to the development of cutaneous leishmaniasis (CL), a disease characterized by frequent ulceration, permanent scarring, and disfigurement. As a neglected tropical disease (NTD), there are over one million new cases of CL annually, with over a billion people worldwide living in Leishmania-endemic areas, particularly among populations living in poverty and in areas of human conflict. Despite this massive global burden of disease, there is no licensed human vaccine against leishmaniasis, and current therapies are variably effective.

A major roadblock to the development of vaccines and novel therapeutics is our incomplete understanding of human immunity to Leishmania in the skin. Dr. Lacsina uses single cell multiomics to define novel immune cell subsets and signaling pathways that orchestrate the human immune response in the skin and blood to Leishmania infection. The laboratory is currently developing spatial profiling methods to define the architecture and tissue organization of human skin immunity to the parasite, with the goal of applying these insights to design and test novel vaccines and targeted therapies against leishmaniasis. These studies are performed in collaboration with the NIAID Leishmaniasis Clinic (Principal Investigator: Dr. Elise O’Connell, Laboratory of Parasitic Diseases). Future work will focus on applying these systems immunology approaches in field studies of CL patients in endemic areas, as well as in broader investigations of human skin immunity in homeostasis, inflammation, and infection.

Clinical Studies

Diagnosis and Treatment of Leishmania Infections. NCT00344188. Associate Investigator.

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans. NCT03641339. Associate Investigator.

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine. NCT04009824. Associate Investigator.

Human Immune Response to Ixodes Scapularis Tick Bites. NCT05036707. Associate Investigator.

Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects. NCT04408950. Associate Investigator.

Sample Collection From Healthy Volunteers for Assay Optimization. NCT03538600. Associate Investigator.

Selected Publications

Matheson AI, Mogeni OD, Lacsina JR, Ochieng M, Audi A, Bigogo G, Neatherlin J, Margolis HS, Fields B, Ahenda P, Walson JL, Montgomery JM. No Evidence of Acute Dengue Virus Infections at a Rural Site in Western Kenya, 2011 and 2013. Am J Trop Med Hyg. 2020 Nov;103(5):2054-2058.

DeSouza-Vieira T, Iniguez E, Serafim TD, de Castro W, Karmakar S, Disotuar MM, Cecilio P, Lacsina JR, Meneses C, Nagata BM, Cardoso S, Sonenshine DE, Moore IN, Borges VM, Dey R, Soares MP, Nakhasi HL, Oliveira F, Valenzuela JG, Kamhawi S. Heme Oxygenase-1 Induction by Blood-Feeding Arthropods Controls Skin Inflammation and Promotes Disease Tolerance. Cell Rep. 2020 Oct 27;33(4):108317.

Lacsina JR, Marks OA, Liu X, Reid DW, Jagannathan S, Nicchitta CV. Premature translational termination products are rapidly degraded substrates for MHC class I presentation. PLoS One. 2012;7(12):e51968.

LaMonte G, Philip N, Reardon J, Lacsina JR, Majoros W, Chapman L, Thornburg CD, Telen MJ, Ohler U, Nicchitta CV, Haystead T, Chi JT. Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. Cell Host Microbe. 2012 Aug 16;12(2):187-99.

Lacsina JR, LaMonte G, Nicchitta CV, Chi JT. Polysome profiling of the malaria parasite Plasmodium falciparum. Mol Biochem Parasitol. 2011 Sep;179(1):42-6.

Visit PubMed for a complete publication list.

Major Areas of Research

Human immunity to Leishmania infection
Systems immunology of human skin: single cell multiomics and multiplex spatial profiling
Global health: human systems immunology at international field sites
Leishmania vaccine development